5-HT receptor antagonist; partial agonist at adrenergic and dopaminergic receptors.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 707.84. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.41 mL||7.06 mL||14.13 mL|
|5 mM||0.28 mL||1.41 mL||2.83 mL|
|10 mM||0.14 mL||0.71 mL||1.41 mL|
|50 mM||0.03 mL||0.14 mL||0.28 mL|
References are publications that support the products' biological activity.
Drago (1988) Dihydroergocristine and memory alterations of aged male rats. Pharmacol.Biochem.Behav. 30 961 PMID: 3147464
If you know of a relevant reference for Dihydroergocristine mesylate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Dihydroergocristine mesylate, supplier, Partial, α-adrenoceptors, α-adrenoceptor, alpha-adrenoceptors, agonists, Non-Selective, dopamine, receptors, partial, α-adrenergic, alpha-adrenergic, a-adrenergic, 5-HT, antagonists, dopaminergic, D2-like, 5-Hydroxytryptamine, Serotonin, 5-HT3, Non-selective, Adrenergic, Alpha, Receptors, Non-selective, Dopamine, Non-selective, 5-HT, 5-HT3, Receptors, Non-selective, Adrenergic, Alpha, Receptors, Tocris Bioscience
Citations for Dihydroergocristine mesylate
Citations are publications that use Tocris products.
Currently there are no citations for Dihydroergocristine mesylate. Do you know of a great paper that uses Dihydroergocristine mesylate from Tocris? If so please let us know.
Dihydroergocristine mesylate Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.